Womb WatchAI
A biotechnology company building an AI operating system for women's health, powered by the Bio-Intent Orchestration System™.
Website: https://www.wombwatchai.com/
PUBLIC
| Attribute | Detail |
|---|---|
| Name | Womb WatchAI |
| Tagline | A biotechnology company building an AI operating system for women's health, powered by the Bio-Intent Orchestration System™. [Womb WatchAI, retrieved 2024] |
| Headquarters | Brooklyn, New York, United States |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.wombwatchai.com
- LinkedIn: https://www.linkedin.com/company/womb-watchai
- Instagram: https://www.instagram.com/wombwatchai/
- Product Site (Rhythm by Womb WatchAI®): https://rhythmbywombwatchai.com
Executive Summary
PUBLIC Womb WatchAI is building an AI operating system for women's health, a bet that merits attention for its technical ambition in a historically underserved and data-poor market [Womb WatchAI, retrieved 2024]. Founded in 2024 by serial tech entrepreneur Quanda Francis, the company's core intellectual property is the Bio-Intent Orchestration System™ (BIOS™), a proprietary AI layer designed to decode thousands of biological variables to personalize health insights and predict risks [WOMEN OF WEARABLES, retrieved 2024]. Its flagship application, Rhythm by Womb WatchAI®, functions as a digital twin platform, tracking symptoms and patterns for conditions like PCOS and endometriosis while offering cancer surveillance features [rhythmbywombwatchai.com, retrieved 2026]. The founder brings a technical profile to the venture, holding multiple patent-pending technologies and personally funding the company's early development [LinkedIn, retrieved 2024] [Instagram, retrieved 2024]. While specific funding rounds are not public, the company has secured backing from the NVIDIA Inception Program and Google for Startups, signaling validation from key ecosystem players, though these are typically non-equity resource programs. Over the next 12-18 months, the critical watchpoints will be the validation of its six proprietary models with clinical or research partners, the conversion of its six provisional patents into granted IP, and the demonstration of user traction that moves beyond the company's claimed 56,000% organic growth rate, a figure that currently lacks independent verification [Instagram, retrieved 2024]. Data Accuracy: YELLOW -- Core product and founder details are confirmed via company and founder profiles; key traction and funding metrics rely on single, unverified sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Company Overview
PUBLIC
Womb WatchAI was founded in 2024 by Quanda Francis, a serial tech entrepreneur who serves as the company's Founder and Chief Technology Officer [WOMEN OF WEARABLES, retrieved 2024]. The company is headquartered in Brooklyn, New York, and positions itself as a biotechnology firm building an AI operating system specifically for women's health [Womb WatchAI, retrieved 2024]. Its founding narrative centers on addressing a significant gap in healthcare research and diagnostics for female-specific conditions, leveraging Francis's background in AI and patent-pending technologies.
Key early milestones include the development of a proprietary AI framework, the Bio-Intent Orchestration System™ (BIOS™), and the filing of six provisional patents [Instagram, retrieved 2024]. The company secured a USPTO trademark for its name in October 2024 [Instagram, retrieved 2024]. In March 2025, Womb WatchAI launched the "Her Health, Her Future" Research Fund, an initiative aimed at directing resources and gathering data to investigate women's biology through AI-driven research [EIN Presswire, 2025]. The company has also gained recognition through participation in prominent startup programs, including the NVIDIA Inception Program and Google for Startups [F6S].
Data Accuracy: YELLOW -- Key founding details are confirmed by the founder's public profile and company materials, but program participation details are from a single aggregator source. The 2025 research fund launch is cited from a press release wire.
Product and Technology
MIXED
The company's core proposition is a proprietary AI system designed to interpret complex biological data for women's health. Womb WatchAI's platform, described as a Bio-Digital Quantum Health AI, is anchored by its Bio-Intent Orchestration System™ (BIOS™), a foundational intelligence layer the company claims can decode over 64,000 biological variables [WOMEN OF WEARABLES, retrieved 2024]. This system powers the flagship consumer-facing product, Rhythm by Womb WatchAI®, an AI-powered app and Digital Twin platform [Womb WatchAI, retrieved 2024]. The application allows users to track a wide array of health indicators, including menstrual cycle symptoms, PCOS indicators, endometriosis pain patterns, nutrition, mood, and lifestyle factors [rhythmbywombwatchai.com, retrieved 2026].
The platform's stated analytical scope is broad, extending from routine wellness to serious disease surveillance. Public materials describe capabilities for period, nutrition, lab, and menstrual flow analysis, with integration into Apple and Google Health ecosystems [Womb WatchAI, retrieved 2024]. A more advanced claimed function is cancer surveillance and population-pattern recognition across five unspecified cancers [Womb WatchAI, retrieved 2024]. The company positions the technology to help decode biological complexity for conditions like endometriosis, PCOS, fibroids, and adenomyosis [Womb WatchAI, retrieved 2024]. A key technical differentiator cited is the training of six proprietary AI models exclusively on female data, a design choice aimed at addressing historical gender bias in medical datasets [Womb WatchAI, retrieved 2024].
Intellectual property forms a central part of the product narrative. The company holds a USPTO trademark secured in October 2024 and reports having six provisional patents filed [Instagram, retrieved 2024]. Founder Quanda Francis is personally credited with four patent-pending technologies, including the BIOS™ [LinkedIn, retrieved 2024]. Beyond the core software, the company has launched a public-facing initiative, the "Her Health, Her Future" Research Fund, announced in 2025 to investigate women's biology through a health questionnaire and direct donations [EIN Presswire, 2025].
PUBLIC
The women's health technology market has moved from a niche concern to a mainstream investment thesis, driven by a confluence of demographic shifts, persistent clinical gaps, and the maturation of enabling technologies like AI and digital biomarkers.
Quantifying the total addressable market for AI-driven women's health platforms is challenging due to the category's nascency, but analogous markets provide a sense of scale. The global digital health market was valued at over $200 billion in 2023 and is projected to grow at a compound annual rate of more than 18% through 2030 [Grand View Research, 2024]. More specifically, the femtech sector, which includes digital solutions for women's health, was estimated at approximately $60 billion globally in 2023 [Frost & Sullivan, 2023]. The segment focused on chronic reproductive conditions like endometriosis and PCOS represents a substantial portion of this, as these conditions affect an estimated 10% and up to 20% of women of reproductive age worldwide, respectively, and have historically been under-diagnosed and poorly managed [Journal of Endometriosis and Uterine Disorders, 2023].
Demand is propelled by several structural tailwinds. A primary driver is the significant and long-standing research gap in women's health, which has led to diagnostic delays averaging 7-10 years for conditions like endometriosis [The Lancet, 2023]. This creates a clear wedge for AI tools that can analyze symptom patterns from patient-reported data. Concurrently, the proliferation of wearable devices and the standardization of health data APIs (like Apple HealthKit and Google Health Connect) have created the raw material,digital biomarkers,for such analysis. Finally, a regulatory push towards patient-centric care and remote monitoring, accelerated by pandemic-era telehealth adoption, is opening reimbursement pathways for digital health tools.
Adjacent and substitute markets include broader chronic disease management platforms (e.g., diabetes care apps like Glooko) and general wellness tracking applications (e.g., MyFitnessPal). However, the specificity required for complex gynecological conditions, which involve tracking hundreds of variables across hormonal, inflammatory, and pain domains, suggests a dedicated platform may have an advantage over generalized tools. The key competitive threat may come from large electronic health record (EHR) vendors or telehealth providers integrating similar AI modules into their existing clinical workflows, rather than from direct-to-consumer app competitors.
Regulatory pathways remain a critical gating factor. In the United States, the FDA's Digital Health Center of Excellence is refining its approach to Software as a Medical Device (SaMD). A platform offering cancer surveillance or diagnostic support would likely require FDA clearance, a process that demands rigorous clinical validation. In contrast, tools positioned for symptom tracking and patient education may operate under a lighter regulatory burden. Macro forces, including potential changes to healthcare privacy laws (HIPAA) and data sovereignty rules, will also influence how sensitive health data can be aggregated and processed across borders.
| Metric | Value |
|---|---|
| Global Digital Health Market (2023) | 200 $B |
| Femtech Sector (2023) | 60 $B |
| Endometriosis Prevalence | 10 % of women |
| PCOS Prevalence | 20 % of women |
The sizing data, while drawn from broader market reports, underscores the substantial population health need and commercial potential. The 10-20% prevalence rates for key conditions translate to tens of millions of potential users in the US alone, supporting a venture-scale opportunity. However, the jump from these broad market figures to a company-specific serviceable obtainable market (SOM) depends entirely on clinical validation, user adoption, and the ability to secure reimbursement,gating factors not yet demonstrated in the public record.
Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports (Grand View Research, Frost & Sullivan) and medical journals, providing a credible analog. Tailwinds and regulatory context are widely reported in trade press. Direct TAM/SAM/SOM for Womb WatchAI's specific offering is not publicly available.
Competitive Landscape
MIXED Womb WatchAI enters a fragmented women's health technology landscape, positioning its proprietary AI system as a foundational intelligence layer rather than a single-point solution.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Womb WatchAI | AI operating system for women's health; Bio-Intent Orchestration System™ (BIOS™) as foundational layer. | Pre-Seed / Undisclosed | Proprietary models trained exclusively on female data; 6 provisional patents; cancer surveillance claims. | [Womb WatchAI, 2024] |
| MindMics | In-ear wearable measuring heart rate variability (HRV) for stress and fitness. | Seed / $3M (2021) | Non-invasive, in-ear form factor for continuous biometric monitoring. | [Crunchbase] |
| Crescent Health | Digital health platform for chronic condition management, including women's health. | Series A / $20M (2023) | Focus on longitudinal care coordination and provider-facing tools. | [Crunchbase] |
| Chorus | Platform for virtual clinical trials and decentralized research. | Series B / $45M (2022) | Infrastructure for conducting large-scale, participant-centric clinical studies. | [Crunchbase] |
| Owaves | Wellness planner app focused on circadian rhythm and time management for health. | Bootstrapped / Undisclosed | Behavioral design approach to structuring daily routines for wellbeing. | [Crunchbase] |
The competitive map divides into three primary segments. Incumbent health tracking platforms like Apple Health and Google Fit offer broad aggregation but lack the disease-specific, predictive analytics Womb WatchAI targets [Womb WatchAI, 2024]. Challengers in the femtech space, such as period tracking apps (e.g., Clue, Flo) and condition-specific platforms, compete on user engagement and symptom logging but typically do not claim an underlying AI operating system or cancer surveillance capabilities. Adjacent substitutes include telehealth providers and electronic health record (EHR) systems, which own the clinical workflow but are not architected for the continuous, multi-variable biological decoding Womb WatchAI describes.
Womb WatchAI's stated defensible edge rests on two pillars: its proprietary dataset and its patent portfolio. The company claims its six AI models are trained exclusively on female data, a technical differentiator in a field where many algorithms are built on male-biased datasets [WOMEN OF WEARABLES, 2024]. Its six provisional patents and a secured trademark for its Bio-Intent Orchestration System™ aim to create regulatory and intellectual property moats [Instagram, 2024]. However, this edge is perishable. The durability depends entirely on the quality, scale, and clinical validation of the underlying dataset, which is not publicly demonstrated. Without published research or peer-reviewed validation of its 64,000+ variable model, the technical claims remain a company assertion.
The company is most exposed in distribution and clinical integration. It lacks the installed user base of mainstream period trackers and the deep EHR integrations of incumbent digital health platforms. A competitor like Crescent Health, with its reported $20 million Series A and focus on provider tools, could replicate the AI analytics layer and deploy it through established healthcare channels more rapidly [Crunchbase]. Furthermore, Womb WatchAI's cancer surveillance claims place it in a highly regulated diagnostic category, an area where it has no announced partnerships with medical institutions or regulatory clearances, creating a significant go-to-market and liability exposure.
The most plausible 18-month scenario hinges on validation and partnership. If Womb WatchAI can convert its provisional patents into issued claims and publish initial research from its "Her Health, Her Future" fund demonstrating predictive accuracy, it becomes an attractive AI module for larger platforms. In this case, a winner could be a telehealth or EHR player seeking to enhance its women's health offerings. Conversely, if the company cannot move beyond founder funding and prototype claims, it risks being outflanked. A loser scenario emerges if a well-capitalized competitor like Chorus leverages its clinical trial infrastructure to build a similar predictive health model, using its existing participant network and regulatory experience to capture the research-oriented segment of the market Womb WatchAI aims to serve.
Data Accuracy: YELLOW -- Competitor funding stages sourced from Crunchbase; Womb WatchAI's differentiators are from its own materials and one third-party profile.
Opportunity
PUBLIC The prize for building a foundational AI layer in women's health is the creation of a multi-billion dollar category leader, capturing value from both direct consumer engagement and the broader healthcare ecosystem that has historically underinvested in female biology.
The headline opportunity is that Womb WatchAI could become the default intelligence layer for women's health, akin to what Epic Systems is for hospital records but built on predictive, personalized AI. The company's core claim is a proprietary system, the Bio-Intent Orchestration System™ (BIOS™), designed to decode over 64,000 biological variables [WOMEN OF WEARABLES, retrieved 2024]. This positions it not as another symptom-tracking app, but as a foundational platform that could integrate with wearables, electronic health records, and clinical research. The cited evidence of six proprietary models trained exclusively on female data and six provisional patents filed [Womb WatchAI, retrieved 2024] [Instagram, retrieved 2024] suggests a technical wedge beyond a simple software wrapper, making the platform outcome reachable if the underlying science is validated.
Growth would likely follow one of several concrete paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Become the Clinical Decision Support Standard | Health systems and OB/GYN clinics license the BIOS™ platform to analyze patient data for early risk detection in conditions like endometriosis and PCOS. | A published validation study from the "Her Health, Her Future" Research Fund demonstrating clinical accuracy. | The company has launched a dedicated research fund to investigate women's biology [EIN Presswire, 2025], providing a direct path to generating the evidence needed for medical adoption. |
| Win the Integrated Wellness Platform Race | The Rhythm app becomes the dominant consumer-facing hub for female health, aggregating data from Apple Health, Google Fit, and connected devices to provide unified insights. | A strategic distribution partnership with a major wearable or smartphone manufacturer. | The product already lists Apple and Google Health integration as a feature [Womb WatchAI, retrieved 2024], and participation in the NVIDIA Inception program provides a potential channel to hardware partners. |
Compounding for Womb WatchAI would manifest as a data network effect. Each user of the Rhythm app contributes longitudinal health data,tracking menstrual cycles, PCOS indicators, and pain patterns [rhythmbywombwatchai.com, retrieved 2026]. This proprietary dataset, focused on a historically under-researched population, would continuously refine the company's AI models. More accurate models would attract more users and, critically, more research and commercial partners seeking access to this differentiated dataset. This creates a classic flywheel: better data leads to a better product, which attracts more users, which generates even better data. The early signal of this flywheel is the claim of 56,000% organic growth, though this metric requires third-party verification [Instagram, retrieved 2024].
The size of the win can be framed by looking at comparable companies targeting adjacent markets. For instance, Oura, a consumer health wearable company focused on general wellness, reached a valuation of approximately $2.5 billion during its last funding round [Bloomberg, 2022]. A company that successfully becomes the AI operating system for the entire women's health vertical,encompassing fertility, chronic condition management, and preventative care,could command a significantly larger premium. If the "Clinical Decision Support Standard" scenario plays out, the company's value could approach the multiples seen in high-growth, software-enabled healthcare technology platforms. This is a scenario-based outcome, not a forecast.
Data Accuracy: YELLOW -- Core technology and product claims are sourced from company materials; growth scenarios are plausible but hinge on unverified future catalysts and partnerships.
Sources
PUBLIC
[Womb WatchAI, retrieved 2024] About Us | Womb WatchAI® - Bio-Digital Quantum Health AI for ... | https://www.wombwatchai.com/about-us
[WOMEN OF WEARABLES, retrieved 2024] WoW Woman in BioTech - Quanda Francis, founder and Chief Technology Officer of Womb WatchAI , WOMEN OF WEARABLES | https://www.womenofwearables.com/new-blog/wow-woman-in-biotech-quanda-francis-founder-and-chief-technology-officer-of-womb-watchai
[Instagram, retrieved 2024] Womb WatchAI - AI Word Wiz Corp. (@wombwatchai) - Instagram | https://www.instagram.com/wombwatchai/
[rhythmbywombwatchai.com, retrieved 2026] Rhythm by Womb WatchAI® | https://rhythmbywombwatchai.com
[LinkedIn, retrieved 2024] Quanda Francis, MBA - Author | Serial Tech Entrepreneur | https://www.linkedin.com/in/quandafrancis
[EIN Presswire, 2025] Her Health, Her Future: The Womb WatchAI Research Fund | https://www.einpresswire.com/article/... (URL inferred from structured facts; specific article URL not provided in raw snippets)
[F6S] Womb WatchAI on F6S | https://www.f6s.com/company/wombwatchai
[Grand View Research, 2024] Digital Health Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/digital-health-market
[Frost & Sullivan, 2023] The Future of Femtech | https://www.frost.com/frost-perspectives/the-future-of-femtech
[Journal of Endometriosis and Uterine Disorders, 2023] Global epidemiology of endometriosis | https://www.sciencedirect.com/science/article/pii/S2949891023000155
[The Lancet, 2023] Endometriosis: a call for action | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00817-9/fulltext
[Crunchbase] MindMics Crunchbase Profile | https://www.crunchbase.com/organization/mindmics
[Crunchbase] Crescent Health Crunchbase Profile | https://www.crunchbase.com/organization/crescent-health
[Crunchbase] Chorus Crunchbase Profile | https://www.crunchbase.com/organization/chorus-ai
[Crunchbase] Owaves Crunchbase Profile | https://www.crunchbase.com/organization/owaves
[Bloomberg, 2022] Oura Valued at $2.55 Billion in Funding Round Led by Temasek and JAZZ Venture Partners | https://www.bloomberg.com/news/articles/2022-04-12/oura-valued-at-2-55-billion-in-funding-round-led-by-temasek-jazz-venture-partners
Articles about Womb WatchAI
- Womb WatchAI's Six AI Models Aim to Decode the Undiagnosed Patient — Founder Quanda Francis is betting a proprietary Bio-Intent Orchestration System can map 64,000 biological variables for conditions like endometriosis and PCOS.